Illumina, Inc. vs ProShares Ultra Semiconductors — how do they compare? Illumina, Inc. trades at $265 (market cap $40.43B), while ProShares Ultra Semiconductors trades at $98.89 (market cap $3.15B). The key difference: Illumina, Inc. is far larger — about 12.8× ProShares Ultra Semiconductors's market cap, and ProShares Ultra Semiconductors is more actively traded (333,862 versus 2,948,626). Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and ProShares Ultra Semiconductors for 29 Days on average.
| ILMN | USD | |
|---|---|---|
Market Cap | $40.43B | $3.15B |
Volume | 2,948,626 | 333,862 |
Sector | Health | Leveraged / Inverse |
52-Week High | $293.69 | $113.53 |
52-Week Low | $91.00 | $43.19 |
Typical Hold Time | 83 Days | 29 Days |
Enterprise Value | $41.79B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
USD stock trades at $102.77, down 0.96% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators with ADX signaling trend strength, though RSI levels suggest potential overbought conditions. Recent corporate action includes a $0.13 dividend scheduled for September 2026. Support levels are established at $100-$102, with resistance at $103-$105.
The stock's technical strength contrasts with limited fundamental data availability. Investment opportunity lies in the bullish technical setup and dividend yield, while risks include potential overbought conditions and lack of current financial metrics. Investors should await updated financial reports for fundamental validation of the current price level.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →